This site is intended for healthcare professionals only
DiabetesontheNet Logo
Sign In / Register

Clinical trials


Multiple Interventions for Diabetic Foot Ulcer Treatment (MIDFUT) trial: benefits of involvement for patients and clinicians
GLP-1 receptor agonists have a wide range of benefits
GLP-1 receptor agonists significantly improve CV outcomes
Canagliflozin effective in primary and secondary prevention of CV outcomes
Semaglutide reduces cardiovascular risk in type 2 diabetes
Renoprotection for patients with diabetes and kidney disease
Canagliflozin is cardioprotective in diabetic kidney disease
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.